Summit Therapeutics (SMMT) Expected to Announce Quarterly Earnings on Tuesday

Summit Therapeutics (NASDAQ:SMMT) is expected to release its Q1 2025 quarterly earnings data on Tuesday, April 29th. Analysts expect Summit Therapeutics to post earnings of ($0.07) per share for the quarter.

Summit Therapeutics (NASDAQ:SMMT) last posted its earnings results on Monday, February 24th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $0.20 million during the quarter. On average, analysts expect Summit Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Summit Therapeutics Stock Down 36.0 %

Summit Therapeutics stock opened at $23.47 on Friday. The business has a 50-day simple moving average of $20.95 and a two-hundred day simple moving average of $20.14. Summit Therapeutics has a 52-week low of $2.10 and a 52-week high of $36.91. The company has a market cap of $17.31 billion, a P/E ratio of -83.82 and a beta of -0.46.

Wall Street Analyst Weigh In

A number of analysts have commented on SMMT shares. Jefferies Financial Group set a $44.00 target price on shares of Summit Therapeutics and gave the company a “buy” rating in a report on Friday. Summit Redstone set a $35.00 target price on Summit Therapeutics in a research report on Wednesday, March 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Summit Therapeutics in a report on Wednesday. Evercore ISI began coverage on Summit Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $30.00 price objective on the stock. Finally, Truist Financial initiated coverage on Summit Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $35.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $36.70.

About Summit Therapeutics

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.